Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.
BCR–ABL
chronic myelyoid leukemia
fusion transcript
major breakpoint cluster region
reverse transcriptase PCR
Journal
Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
02
2021
revised:
08
05
2021
accepted:
13
05
2021
entrez:
29
6
2021
pubmed:
30
6
2021
medline:
30
6
2021
Statut:
epublish
Résumé
Depending on breakpoints of rearrangement different types of BCR-ABL fusion protein can be generated in patients of chronic myeloid leukemia (CML). The aim of this study is to observe frequencies of major transcripts in CML patients by reverse transcriptase polymerase chain reaction (RT-PCR) and their hematological features at the time of presentation. This cross sectional study was performed at Molecular Lab of Riphah International University, Islamabad from January to June 2019. Consecutive peripheral blood samples of 70 newly diagnosed CML patients in chronic phase were analyzed by RT-PCR to detect different BCR-ABL transcripts. Routine blood cell counts were assessed by an automated hematology analyzer. All samples expressed typical BCR-ABL rearrangement. Expression of either e14a2 or e13a2 transcript was detected in 38 (54%) and 30 (43%) patients, respectively. Coexpression of e13a2 + e14a2 was found in 2 (3%) patients. The mean total leukocyte count was higher in group expressing e13a2 ( e14a2 transcript was most common transcript in CML patients. Patients exhibiting e13a2 subgroup presented with significantly higher mean white blood cell count at the time of presentation. Significantly higher proportion of male patients was found to express e14a2 transcript over e13a2.
Sections du résumé
BACKGROUND
BACKGROUND
Depending on breakpoints of rearrangement different types of BCR-ABL fusion protein can be generated in patients of chronic myeloid leukemia (CML). The aim of this study is to observe frequencies of major transcripts in CML patients by reverse transcriptase polymerase chain reaction (RT-PCR) and their hematological features at the time of presentation.
MATERIALS AND METHODS
METHODS
This cross sectional study was performed at Molecular Lab of Riphah International University, Islamabad from January to June 2019. Consecutive peripheral blood samples of 70 newly diagnosed CML patients in chronic phase were analyzed by RT-PCR to detect different BCR-ABL transcripts. Routine blood cell counts were assessed by an automated hematology analyzer.
RESULTS
RESULTS
All samples expressed typical BCR-ABL rearrangement. Expression of either e14a2 or e13a2 transcript was detected in 38 (54%) and 30 (43%) patients, respectively. Coexpression of e13a2 + e14a2 was found in 2 (3%) patients. The mean total leukocyte count was higher in group expressing e13a2 (
CONCLUSION
CONCLUSIONS
e14a2 transcript was most common transcript in CML patients. Patients exhibiting e13a2 subgroup presented with significantly higher mean white blood cell count at the time of presentation. Significantly higher proportion of male patients was found to express e14a2 transcript over e13a2.
Identifiants
pubmed: 34183996
doi: 10.1515/med-2021-0309
pii: med-2021-0309
pmc: PMC8223518
doi:
Types de publication
Journal Article
Langues
eng
Pagination
904-912Informations de copyright
© 2021 Huma Amin and Suhaib Ahmed, published by De Gruyter.
Déclaration de conflit d'intérêts
Conflict of interest: There was no conflict of interest.
Références
Blood. 1990 Jan 15;75(2):445-52
pubmed: 2403827
J Mol Diagn. 2004 Nov;6(4):343-7
pubmed: 15507673
Mol Genet Genomic Med. 2019 Aug;7(8):e809
pubmed: 31206255
Genet Mol Res. 2008 Oct 21;7(4):1138-49
pubmed: 19048492
Leukemia. 2013 Aug;27(8):1650-8
pubmed: 23434731
Crit Rev Oncol Hematol. 2016 Jan;97:263-74
pubmed: 26412717
BMC Res Notes. 2018 Nov 1;11(1):780
pubmed: 30382890
Blood. 2000 Nov 15;96(10):3343-56
pubmed: 11071626
Oncologist. 2002;7 Suppl 1:30-8
pubmed: 11961207
Leuk Res. 2008 Apr;32(4):579-85
pubmed: 17928051
Indian J Med Paediatr Oncol. 2014 Jan;35(1):26-30
pubmed: 25006280
Indian J Med Res. 2012;135:42-8
pubmed: 22382182
Cancer Res. 2001 Mar 15;61(6):2343-55
pubmed: 11289094
Transl Res. 2006 Nov;148(5):249-56
pubmed: 17145570
Med J Malaysia. 2018 Apr;73(2):78-85
pubmed: 29703870
Leuk Lymphoma. 2013 Jul;54(7):1411-7
pubmed: 23121646
Acta Med Indones. 2013 Apr;45(2):107-13
pubmed: 23770790
Genet Mol Res. 2017 Apr 20;16(2):
pubmed: 28437552
J Coll Physicians Surg Pak. 2014 Mar;24(3):190-3
pubmed: 24613116
Am J Hematol. 2006 Nov;81(11):845-9
pubmed: 16888785
Hematol Rep. 2011 Jan 13;3(1):e3
pubmed: 22184525
Am J Hematol. 2004 Oct;77(2):164-6
pubmed: 15389825
Blood. 2011 Jun 23;117(25):6793-800
pubmed: 21447834
Arch Iran Med. 2008 May;11(3):247-51
pubmed: 18426313
Hematol Transfus Cell Ther. 2019 Apr - Jun;41(2):114-118
pubmed: 31079657
J BUON. 2016 Mar-Apr;21(2):444-9
pubmed: 27273956
J Pak Med Assoc. 2020 Oct;70(10):1748-11752
pubmed: 33159746
Br J Haematol. 2010 Mar;148(5):739-53
pubmed: 19958356
Ther Adv Hematol. 2016 Oct;7(5):237-251
pubmed: 27695615
Blood. 2016 Mar 10;127(10):1269-75
pubmed: 26729897
J Oncol. 2016;2016:8420853
pubmed: 27313614
Indian J Cancer. 2015 Jul-Sep;52(3):314-8
pubmed: 26905124